Salem's obesity gap over Oregon, the March 2026 OHP weight-management criteria, two clinics that name the drugs but not the cost, and a Marion/Polk shortage designation.
41.4% of Salem adults live with obesity, a crude prevalence figure from CDC PLACES drawn from 2023 BRFSS data 1. That is 7.8 percentage points above Oregon's statewide rate of 33.6% for the same year 2, one of the wider city-over-state gaps among Oregon's mid-size cities.
Salem's rate sits inside a metro of 443,416 people, Marion and Polk Counties combined 4, anchored by a city of 180,406 residents 3, with a median household income of $79,638 and 7.8% uninsured 5.
The most consequential local coverage decision this year came from the state, not a Salem clinic. Oregon Health Plan runs its fee-for-service pharmacy benefit through a Preferred Drug List with prior-authorization criteria reviewed by the Oregon Health Authority's P&T and DUR committees. The Weight Management Drugs criteria were reviewed February 26, 2026 and took effect March 1, 2026, and they draw a hard line: GLP-1 drugs prescribed for weight management alone, with no other qualifying diagnosis, are not covered for adults under the fee-for-service benefit 9.
Semaglutide (Wegovy) clears prior authorization only with an established cardiovascular disease diagnosis or MASH/NASH liver disease; tirzepatide (Zepbound) only for moderate-to-severe obstructive sleep apnea paired with obesity at BMI 30 or above. An adult in Marion County whose only diagnosis is obesity or overweight does not qualify. Adolescents aged 12-17 can qualify on an obesity or overweight diagnosis alone through a case-by-case EPSDT pathway with a lifestyle-modification program and a documented prior weight-loss attempt of at least three months 9. One caveat: this is the fee-for-service floor, and most OHP members enroll through a Coordinated Care Organization that can layer its own formulary rules on top, so actual coverage can depend on the assigned CCO.
Two clinics inside city limits talk publicly about GLP-1 medications, and neither publishes what the drug costs per month. Neaman Wellness Center, at 1430 Commercial Street SE, runs a standing offer of $99 for a first-visit consultation, 50% off the normal $199, bundled with an InBody body-composition scan. Its service page names semaglutide, tirzepatide, and retatrutide in a side-by-side mechanism comparison, more detail than most clinics offer, but the injection price is set after that paid visit rather than published. Checked 2026-08-28 7.
AIYANA Med, at 120 Commercial St NE Suite 350, lists tirzepatide and semaglutide inside its 12-month EMBODY membership. Its Salem-specific service page returns a 404, and the closest comparable page, for AIYANA's Molalla location, carries no price at all, only a phone number. Checked 2026-08-28 8.
That is the pattern: two real Salem clinics, two real medications named, zero public monthly prices. Astra's price is flat and public: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans, $816 and $1,416 billed annually, the same whether you're in Salem, Portland, or anywhere else Astra treats patients.
No blanket geographic Primary Care HPSA covers Salem as a whole. Two Salem-based facilities carry current designations instead: Northwest Human Services, Inc. (score 20, designated 10/26/2002, service population 78,899) and the Chemawa Indian Health Center (score 17, designated 10/26/2002, service population 25,794). Layered over the area, a county-wide Low Income Population HPSA for Marion and Polk Counties (score 15, updated 11/06/2025) covers 130,940 residents with a modeled shortage of 32.85 full-time-equivalent primary-care providers. Six nearby Mid-Willamette Valley towns, Stayton, Silverton, Mount Angel, Sublimity, Aumsville, and Woodburn, carry their own active designations 6.
HRSA issues no shortage category for endocrinology or bariatric medicine, so there is no official Salem specialist wait-time number to cite. Qualitatively, dedicated obesity-medicine and endocrinology capacity concentrates in larger regional hospital systems rather than freestanding Salem practices, while the local primary-care base runs through Salem Health, Kaiser Permanente, Legacy Health, and the community health centers already carrying safety-net designations.
That is the gap telehealth closes: a licensed clinician, no referral into an already-strained local system, and a prescription that ships. See the Oregon GLP-1 overview for statewide context.
Astra treats patients in Oregon through state-licensed physicians.
Hard to say for certain, because Salem's clinics don't publish a medication price to compare against. Neaman Wellness Center advertises a $99 first-visit consultation (50% off $199) with an InBody scan, but sets the actual injection price only after that visit. AIYANA Med names semaglutide and tirzepatide in its 12-month membership but shows no drug price anywhere on its site — its Salem page returns an error, and its comparable-city page tells callers to phone in instead. Astra's price is public and flat: $68/mo for semaglutide, $118/mo for tirzepatide, 12-month plans, the same in Salem as anywhere else in Oregon.
Generally not for adults using weight loss as the only diagnosis. Oregon Health Plan's Fee-for-Service Preferred Drug List (reviewed February 2026, effective March 1, 2026) states GLP-1 drugs prescribed for weight management alone are not covered for adults. Semaglutide (Wegovy) is covered only with diagnosed cardiovascular disease or MASH/NASH liver disease; tirzepatide (Zepbound) only for moderate-to-severe obstructive sleep apnea with obesity (BMI ≥30). Adolescents 12-17 can qualify for obesity alone through a case-by-case EPSDT pathway. Most Marion County OHP members enroll through a Coordinated Care Organization, which can add its own rules on top of this state floor.
Both Salem clinics that publicly discuss GLP-1 medications wall the actual drug cost off behind a required visit. Neaman Wellness Center publishes only a discounted consultation fee ($99, normally $199) with an InBody scan — not a medication price. AIYANA Med names semaglutide and tirzepatide in its service list, but its own Salem page returns an error and its comparable-city page tells visitors to call rather than listing a number. Astra publishes its full national price up front: $68/mo semaglutide, $118/mo tirzepatide, 12-month plans.
Salem's adult obesity rate is 41.4% (crude prevalence, CDC PLACES, BRFSS 2023 data) — 7.8 percentage points above Oregon's statewide rate of 33.6% (BRFSS 2023). That's one of the wider city-over-state gaps seen among Oregon's mid-size cities.
Yes. Astra is licensed to treat patients in all 50 states, including Oregon, so Salem residents can complete an online visit and, if appropriate, get semaglutide or tirzepatide prescribed and shipped without an in-person visit to a local clinic.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.